ClinicalTrials.gg
CompletedNCT04018599Updated Mar 25, 2020

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

A Phase 1 interventional study of 40 mg MSB11022 and 40 mg MSB11022 in Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
38th of 87
216 · median 160
Started
2019
with 3 others
Phase 1
2 of 87
none open now
Registered
80th of 87
by date
Lead sponsor
2 of 87
Fresenius Kabi SwissBioSim GmbH

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 38th largest by enrollment, is one of 4 that started in 2019, is one of 2 in phase 1, and was the 80th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection of 40 mg.

03

Conditions studied

  • Rheumatoid Arthritis
  • Polyarticular Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Pediatric Plaque Psoriasis
  • Pediatric Crohns Disease
  • Hidradenitis Suppurativa
  • Non-infectious Uveitis

Keywords

  • Biosimilar
  • Adalimumab
  • MSB11022
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to sign the form (ICF).
  2. Healthy male subjects and female subjects of non-childbearing and .
  3. Aged 18 to 55 years, inclusive, at screening.
  4. Have all screening results (vital signs, physical examination, clinical laboratory tests, 12-lead ) within the normal range or outside the normal range but assessed as not by the Investigator.
  5. Body weight between 50.0 and 100.0 kg, inclusive, and a between 18.5 and 30.0 kg/m2, inclusive.
  6. Male subjects must be either surgically sterile or willing to use methods until 5 months after the dose of medicinal product (IMP).
  7. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and before randomization. WOCBP must agree to use highly effective methods of contraception to prevent pregnancy for at least 4 weeks before randomization until 5 months after the dose of IMP. For all female subjects, serum follicle-stimulating hormone (FSH) is tested at screening to identify their postmenopausal status.
  8. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and all other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects must not be pregnant or lactating at screening through at least 5 months after the last treatment with IMP.
  2. A history and/or current presence of atopic allergy (eg, asthma including childhood asthma), or allergic reactions (either spontaneous or following drug administration), including known or suspected clinically relevant drug hypersensitivity to any components of the study drug formulations, comparable drugs, or to latex. Mild hay fever is allowed if outside of acute exacerbation requiring treatment. Assessment of clinical significance of reported atopic or allergic condition in medical history of participant is at Investigator decision.
  3. Have either active or latent tuberculosis (TB) as indicated by a positive QuantiFERON®-TB Gold test or have a history of TB. Subjects who have an indeterminate QuantiFERON-TB Gold test result may be re-tested once during screening. If the re-test result is negative, the subject is eligible to participate in the study. If the re-test result is indeterminate again or positive, the subject is NOT eligible to participate in the study.
  4. Lifetime history of invasive systemic fungal infections (eg, histoplasmosis) or other opportunistic infections, including recurrent or chronic local fungal infections.
  5. Have had a serious infection (associated with hospitalization and/or which required intravenous anti-infectives or intravenous antibiotics) within 6 months prior to study drug administration and/or a significant infection (excluding resolved infections like a mild common cold) within 2 weeks prior to the screening or during the screening period unless the infection has resolved completely within 2 weeks before admission.
  6. Have had herpes zoster

    1. within the last year, or
    2. more than 2 herpes zoster infections in their lifetime prior to randomization.
  7. History or presence (at time of screening or randomization) of frequent (ie, requiring treatment more than 3 times a year), chronic or recurrent infections.
  8. Have previously been exposed to adalimumab or approved or proposed adalimumab biosimilar drugs if known. Have been exposed to any anti-tumor necrosis factor alfa class drug whether approved drug or drug\proposed biosimilar.
  9. Intake of an investigational drug in another study within 3 months or 5 half-lives, whichever is longer, before the intake of the IMP in this study or planned intake of an investigational drug during the course of this study.
  10. Use of depot injectable solutions (except for depot drugs) within 6 months before randomization.
  11. Smoking more than equivalent of (as determined by investigator) 10 cigarettes per day and/or inability to refrain from smoking or consuming nicotine containing products during the residential stay at the trial site.
  12. History of alcohol abuse within one year from screening and/or inability to refrain from intake of alcoholic beverages from 48 hours prior to Day -1 until Day 14 postdose or a positive screen for alcohol on admission to the clinical site prior to study drug administration.
  13. Positive screen for drugs of abuse at screening or at admission to the clinical site prior to study drug administration.
  14. Donated more than 450 mL of blood within 60 days or 450 mL of blood products (eg, plasma, ) within 2 weeks prior to admission to the clinical site or intend to donate during the study.
  15. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), dietary supplements or herbal medication during the 2 weeks prior to study drug administration or longer if the medication has a long half-life. For female subjects, oral contraceptives and hormone replacement therapy are allowed.
  16. History of cancer including lymphoma, leukemia, and skin cancer.
  17. Impaired liver function as determined at screening or admission to the clinic by one of the following:

    • Serum (ALT) and/or aspartate aminotransferase (AST) >1.5 times the (ULN) at screening or admission to the clinic.
    • A positive virus (HCV) antibody test or surface antigen (HBsAg) test and/or core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM) at screening.
  18. History of or current signs or symptoms of demyelinating disease including optic neuritis and/or multiple sclerosis.
  19. History of immunodeficiency (including a positive test for [HIV] 1 or 2 antibodies) or other clinically significant immunological disorders, or disorders, (eg, rheumatoid arthritis, lupus erythematosus, scleroderma).
  20. History of and/or current gastrointestinal, renal, cardiovascular, hematological (including pancytopenia, aplastic anemia or blood dyscrasia), metabolic (including known diabetes mellitus), central nervous system or pulmonary disease considered as significant by the Investigator.
  21. Received a within 12 weeks prior to screening visit or plan for any such vaccination during the study or within 4 months after study drug administration.
  22. Any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or lesions in the areas intended for s.c. injection, that in opinion of Investigator do not allow assessment of local tolerability.
  23. Legal incapacity or limited legal capacity.
  24. Significant concurrent disease or a known medical condition which would make the participant unfit to participate in the study as per Investigator assessment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    40 mg MSB11022 via Auto-injector

    Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.

    Drug: 40 mg MSB11022

  • Experimental
    40 mg MSB11022 via Pre-filled Syringe

    Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.

    Drug: 40 mg MSB11022

Interventions

  • Single dose, as a solution, administered subcutaneously, using an auto-injector.

  • Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

Secondary outcomes

  1. Time to Reach the Maximum Plasma Concentration (Tmax) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

  2. Terminal Rate Constant (λz) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

  3. Terminal Half-life (t1/2) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

  4. Apparent Total Clearance (CL/F) for MSB11022

    Time frame: Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose

  5. Number of Participants with at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment AE. A TEAE is an AE that occurs only once treatment has started.

    Time frame: Day 1 (post-dose) to Day 71

  6. Number of Participants with at Least One Serious Adverse Event (SAE)

    An SAE is defined as an AE occurring during any study phase that fulfills one or more of the following criteria: * Results in death. * Requires hospitalization (in-patient treatment) or prolongation of existing hospitalization. * Is life-threatening. * Results in persistent or significant disability or incapacity. * Is a congenital anomaly or birth defect. * Is otherwise considered to be medically important.

    Time frame: Screening (up to 28 days prior to study admission) to Day 71

  7. Number of Participants with at Least One Adverse Event of Special Interest (AESI)

    An AESI is defined as a hypersensitivity reaction of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or above.

    Time frame: Screening (up to 28 days prior to study admission) to Day 71

  8. Number of Participants with an Injection Site Reaction (ISR)

    Local tolerability will be assessed be evaluating the site of administration. The investigator or designee will check for the presence of injection site reactions, including, erythema, rash, tenderness, swelling, itching, bruising, or other abnormalities.

    Time frame: Day 1 (post-dose) to Day 71

  9. Number of Participants who Experience a Clinically Significant Change in Vital Sign Results

    Vital sign measurements will include Systolic and diastolic blood pressure, pulse, body temperature and respiratory rate.

    Time frame: Screening (up to 28 days prior to study admission) to Day 71

  10. Number of Participants who Experience a Clinically Significant Change in Clinical Laboratory Results

    Parameters will include clinical chemistry, coagulation, hematology, urinalysis and serology.

    Time frame: Screening (up to 28 days prior to study admission) to Day 71

  11. Number of Participants who Experience a Clinically Significant Change in Electrocardiogram (ECG) Results

    A standard 12-lead ECG will be used.

    Time frame: Screening (up to 28 days prior to study admission) to Day 71

07

Study locations

2 sites
  • PRA Health Sciences (PRA) - Early Development Services (EDS)
    Lenexa, Kansas 66219, United States
  • PRA-EDS
    Salt Lake City, Utah 84124, United States
08

References and documents

Publications

  • Sabet A, Dickerson DS, Kunina EE, Buccarello AL, Monnet J. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects. Rheumatol Ther. 2022 Apr;9(2):693-704. doi: 10.1007/s40744-022-00432-1. Epub 2022 Mar 9. PubMed 35262901 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Mar 2020, 8 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 12, 2019
StartActual
Jul 15, 2019
Primary completionActual
Mar 17, 2020
CompletionActual
Mar 17, 2020
Last update
Mar 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04018599
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Jul 12, 2019
Start date
Jul 15, 2019
Primary completion
Mar 17, 2020
Completion
Mar 17, 2020
Last update
Mar 25, 2020

Study contacts

Radmila Kanceva, MD, PhD
study director · Fresenius Kabi SwissBioSim GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion